Chinese SPC elucidates test for evaluating common knowledge evidence

Yue Guan of Wanhuida Intellectual Property analyses a decision by the China National Intellectual Property Administration on the validity of a pulmonary hypertension drug and the implications for pharmaceutical patentees

Related Keywords

,Actelion Pharmaceuticals ,China National Intellectual Property Administration ,World Intellectual Property Day ,Top Ten Patent Reexamination ,Invalidation Cases ,